Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Authors:
- 1 July 2019
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (19) , 1657-1665
Abstract
PURPOSE: The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities. The current definition of high-risk profile is restrictive and oversimplified. To adapt MM treatment to risk, we need to better define a cytogenetic risk classification. To address this issue, we simultaneously examined the prognostic impact of del(17p); t(4;14); del(1p32); 1q21 gain; and trisomies 3, 5, and 21 in a cohort of newly diagnosed patients with MM. METHODS: Data were obtained from 1,635 patients enrolled in four trials implemented by the Intergroupe Francophone du Myélome. The oldest collection of data were used for model development and internal validation. For external validation, one of the two independent data sets was used to assess the performance of the model in patients treated with more current regimens. Six cytogenetic abnormalities were identified as clinically relevant, and a prognostic index (PI) that was based on the parameter estimates of the multivariable Cox model was computed for all patients. RESULTS: In all data sets, a higher PI was consistently associated with a poor survival outcome. Dependent on the validation cohorts used, hazard ratios for patients in the high-risk category for death were between six and 15 times higher than those of patients in the low-risk category. Among patients with t(4;14) or del(17p), we observed a worse survival in those classified in the high-risk category than in those in the intermediate-risk category. The PI showed good performance for discriminating between patients who died and those who survived (Harrell’s concordance index greater than 70%). CONCLUSION: The cytogenetic PI improves the classification of newly diagnosed patients with MM in the high-risk group compared with current classifications. These findings may facilitate the development of risk-adapted treatment strategies.Keywords
This publication has 30 references indexed in Scilit:
- Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myelomaMolecular Cytogenetics, 2017
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Blood, 2015
- Erratum: Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center studyBlood Cancer Journal, 2015
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsBlood, 2012
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialLeukemia, 2011
- Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 TrialsJournal of Clinical Oncology, 2009
- Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaLeukemia, 2006
- Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocationsLeukemia, 2006
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyBlood, 2005